A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

Launched by MERCK SHARP & DOHME LLC · Oct 21, 2024

Keywords

ClinConnect Summary

This clinical trial, called V350-001, is studying two new vaccines (V350A and V350B) designed to help prevent diseases related to the Epstein Barr virus (EBV), which can cause conditions like infectious mononucleosis and is linked to certain types of cancer and multiple sclerosis. The main focus of this study is to assess how safe and tolerable these vaccines are for healthy adults. If you’re between the ages of 65 and 74 and are in good health with a body mass index (BMI) between 18 and 35, you may be eligible to participate.

Participants in this trial can expect to receive either of the vaccines and will be monitored for any side effects or reactions. It’s important to know that individuals who have had infectious mononucleosis in the past year or have conditions that weaken their immune system cannot take part in this study. By joining this trial, you could help researchers understand how these vaccines may protect against EBV-related diseases in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The key inclusion criteria include but are not limited to the following:
• • Is in good health before randomization.
• • Has a body mass index ≥18 and ≤38 kg/m\^2, inclusive.
• Exclusion Criteria:
• The key exclusion criteria include but are not limited to the following:
• • Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment.
• • Has any immunosuppressive medical condition or receive any immunosuppressive therapy.